Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Table: S219A
Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Result: By analysing the overlapping between the HBsAg and RT genes, sP203Q did not result in any amino acid substitution in RT, while sS210R corresponded to rtS219A.
Result: The percentage of patients with sS210R/rtS219A was comparable between drug naive HCC-patients (33.3%, 3/9) and drug-treated HCC-patients (35.7%, 5/14), thus excluding the impact of antiviral therapy on the selection of this mutation.
Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and Sao Paulo, Brazil.
Abstract: The other samples showed only compensatory mutations, such as rtL80F (5.88%), rtL80V (2.94%), rtL82V + rtV207L (2.94%), rtT128P (5.88%), rtT128N/S (2.94%) and rtS219A (5.88%).
Result: Among the 13 subjects from Sao Paulo, we detected only the rtS219A + sS210R mutations.
Result: The other samples showed only the compensatory mutations
Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
Abstract: In this pattern, the S219A and Y245H mutations mainly seem to contribute to the emergence of ETV resistance.
Abstract: RESULTS: Dominance of a clone carrying L80LV, L91I, M204I, S219A, N238D, Y245H changes was detected in the last serum sample of the patient just before his death.
Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.
Result: The virus from patient 12 had an S219A mutation, which reverted to the wild-type when 3TC resistance mutations V173L, L180M and M204V were acquired.
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
PMID: 19008175
2008
European journal of medical research
Abstract: Because of unchanged VL sequence analysis was performed three months later, which showed the mutation (rtS219A) and the concomitant mutation (sS210R) and 2 mutations in core promoter region (A1762T), (G1764A).
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
Abstract: On sequencing, variant rt217R (associated with subgenotype A2) was predictive of non-CVR (100%) and non-PVR (72.7%); the rtS219A variant emerged during therapy in three non-PVR patients.
HBV mutation literature information.
PMID: 
2022
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT